Hypertrophic cardiomyopathy
Cytokinetics shares positive phase 3 results for aficamten in heart disease
Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
The neurodegenerative disease affects approximately 27,000 people in the US
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
BMS gained the rights to mavacamten as part of its acquisition of MyoKardia
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death
Amgen agrees to take Cytokinetics’ heart failure drug into phase III
Phase II results showed significant cardiac function benefit and no adverse safety signals
Biogen buys into Ionis’ nusinersen after positive phase III trial
Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”
Astellas forges $675m muscle alliance with Cytokinetics
Extendscollaboration to include neuromuscular diseases
Amgen drug misses endpoint in acute heart failure trial
Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure